Your browser doesn't support javascript.
loading
An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases.
Petri, László; Egyed, Attila; Bajusz, Dávid; Imre, Tímea; Hetényi, Anasztázia; Martinek, Tamás; Ábrányi-Balogh, Péter; Keseru, György M.
Afiliação
  • Petri L; Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary.
  • Egyed A; Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary.
  • Bajusz D; Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary.
  • Imre T; MS Metabolomics Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary.
  • Hetényi A; Department of Medicinal Chemistry, University of Szeged, Dóm Tér 8, H-6720, Szeged, Hungary.
  • Martinek T; Department of Medicinal Chemistry, University of Szeged, Dóm Tér 8, H-6720, Szeged, Hungary.
  • Ábrányi-Balogh P; Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary.
  • Keseru GM; Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary. Electronic address: keseru.gyorgy@ttk.hu.
Eur J Med Chem ; 207: 112836, 2020 Dec 01.
Article em En | MEDLINE | ID: mdl-32971426
ABSTRACT
Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different disease pathologies. Although a number of computational protocols have been published for identifying druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique opportunity for the efficient integration of warhead-optimization and target-validation into the covalent drug development process. Screening this probe kit against multiple kinases could experimentally characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retrospectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor programs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cisteína / Janus Quinase 3 / Bibliotecas de Moléculas Pequenas Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cisteína / Janus Quinase 3 / Bibliotecas de Moléculas Pequenas Idioma: En Ano de publicação: 2020 Tipo de documento: Article